Evidence map›Paper›PMID 29066476›Full record

ArticleAnnals of clinical and laboratory science2017

Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma.

Maha El Naofal, Adriel Kim, Hui Yi Yon, Mohamed Baity, Zhao Ming, Jacquelin Bui-Griffith, Zhenya Tang, Melissa Robinson, Elizabeth G Grubbs, Gilbert J Cote and 1 more

Abstract readComparative StudyValidation Study
PubMed Full text at PMC
In one paragraph

Article in Annals of clinical and laboratory science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Maha El NaofalSchool of Health Professions Program in Diagnostic Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adriel KimSchool of Health Professions Program in Diagnostic Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hui Yi YonSchool of Health Professions Program in Diagnostic Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mohamed BaitySchool of Health Professions Program in Diagnostic Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhao MingProgram in Cytogenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jacquelin Bui-GriffithDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhenya TangDepartment of Clinical Cytogenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Melissa RobinsonDepartment of Clinical Cytogenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth G GrubbsDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gilbert J CoteDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peter HuSchool of Health Professions Program in Diagnostic Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA pchu@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPOREP50CA168505 · NCI · OHIO STATE UNIVERSITY · PI KIRSCHNER, LAWRENCE S · 2013 to 2017
$10.9M
NCI NIH HHS P50 CA168505
6 · The paper itself

Abstract

Medullary thyroid carcinoma (MTC), an aggressive form of thyroid cancer, occurs sporadically in approximately 75% of MTCs.

Indexed as

Cancer Care FacilitiesCarcinoma, NeuroendocrineChromosomes, Artificial, BacterialCyclin-Dependent Kinase Inhibitor p18Cyclin-Dependent Kinase Inhibitor p19Cytogenetic AnalysisDNA, ComplementaryDNA, RecombinantFeasibility StudiesGene DeletionHumansIn Situ Hybridization, FluorescenceLoss of HeterozygosityNeoplasm ProteinsPrognosisRecombinant ProteinsCDKN2C protein, humanCDKN2D protein, humanCyclin-Dependent Kinase Inhibitor p18Cyclin-Dependent Kinase Inhibitor p19DNA, ComplementaryDNA, RecombinantNeoplasm ProteinsRecombinant ProteinsFISHMTCRASRET

Identifiers

PMID29066476
PMCPMC7057027
OpenAlexW2766272028

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.